DURECT (DRRX) CEO Receives Two Option Grants Totaling 261,923 Shares
Rhea-AI Filing Summary
James E. Brown, President & CEO and a director of DURECT Corporation (DRRX), reported two option grants on 09/09/2025 and 09/10/2025. Each grant is reported with transaction code M (award of options) for 131,923 and 130,000 stock options respectively, both with an exercise price of $1.30 and an expiration date of 10/14/2034. The filings show post-transaction direct beneficial ownership of 415,335 shares after the first grant and 545,335 shares after the second grant, plus 8,000 shares held indirectly by the Brown Family Trust dated 5/10/2006. The options vest in installments of one-sixteenth every three months following the grant, subject to continuous service.
Positive
- CEO received equity-based compensation through two option grants (131,923 and 130,000 options) which align incentives with shareholder value
- Vesting schedule clearly disclosed: options vest in one-sixteenth increments every three months, providing transparency on service-based vesting
- Long-dated expiry (10/14/2034) gives extended period for potential value realization
Negative
- None.
Insights
TL;DR: Routine executive option grants to CEO/director, structured with multi-period vesting and long expiry, typical for retention.
The Form 4 discloses two stock option awards to the reporting person in successive days totaling 261,923 options at a $1.30 exercise price, expiring 10/14/2034. Vesting is gradual—one-sixteenth every three months—indicating multi-year retention conditioning. Reported direct beneficial ownership increases to 545,335 shares after the second grant and there is an 8,000 indirect holding via a family trust. From a governance perspective, the disclosure is complete and follows Section 16 reporting norms; the structure aligns executive incentive design focused on long-term service.
TL;DR: Compensation action: two stock-option awards with staggered vesting and a long expiration horizon, consistent with retention incentives.
The filing documents option awards on 09/09/2025 (131,923 options) and 09/10/2025 (130,000 options) exercisable at $1.30 and expiring on 10/14/2034. The vesting schedule—one-sixteenth of the grant every three months—creates a four-year+ cliff to full vesting, tying realized value to continued service. The Form 4 also lists derivative holdings following the grants (233,077 and 130,000 underlying shares reported in the derivative table) and increases total reported direct ownership. This is a standard compensation mechanism; no additional performance metrics or acceleration clauses are disclosed on the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 130,000 | $0.00 | -- |
| Exercise | Common Stock | 130,000 | $1.30 | $169K |
| Exercise | Stock Option (right to buy) | 131,923 | $0.00 | -- |
| Exercise | Common Stock | 131,923 | $1.30 | $171K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Held by the Brown Family Trust DTD 5/10/2006. The option will vest and become exercisable in installments of one-sixteenth (1/16) of the total number of shares at the end of each three-month period following the grant date, subject to the Reporting Person providing continuous service to the Issuer through the applicable vesting date.
FAQ
Who filed the Form 4 for DRRX and what is their role?
What securities were reported in the 09/09/2025 and 09/10/2025 transactions?
What is the exercise price and expiration date of the reported options?
How do the options vest according to the filing?
What is the reporting person's beneficial ownership after the transactions?